NIOX Group Plc

NIOX Group Plc is a worldwide company dedicated to innovating, developing, and distributing medical devices that measure fractional exhaled nitric oxide (FeNO). A key product is the NIOX VERO system, an easily portable and non-invasive diagnostic tool designed for immediate, on-site patient use. This system includes a compact device alongside a suite of disposable items like sensors, individual mouthpieces, and breathing handles, all essential for quantifying FeNO levels in patients. The company, which was founded in 2006 and is headquartered in Oxford, United Kingdom, was formerly known as Circassia Group Plc until its renaming to NIOX Group Plc in September 2022.

NIOX Group Plc trades as NIOX.L on LSE. The company is classified in Healthcare / Medical - Devices and reports in GBP.

The current profile places the business in Medical - Devices. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows £48.70M of revenue and £7.00M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

NIOX Group Plc can be compared against peers such as Allergy Therapeutics plc, Advanced Medical Solutions Group plc, Animalcare Group plc, Avacta Group Plc, Beximco Pharmaceuticals Limited, Diaceutics PLC.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £251.68M, beta of -0.06, and return on equity of +9.5%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

NIOX.L currently shows total debt of £1.00M and beta of -0.06. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://investors.niox.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.